Updates from MariTide & Orforglipron research
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
There are promising GLP1 Receptor Agonists on the horizon, both in injection form and pill based forms. MariTide is one of them (formerly known as AMG-133) and Orforglipron is another:
Amgen’s GLP1: AM-133
Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it’s got any promise.
GLP1.Guide Staff
Eli Lilly’s other new GLP1 - Orforglipron
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It’s not easy to pronounce, but it is easy to take, and easy to produce.
GLP1.Guide Staff
We've covered both of these before, but what's important/interesting is that there has just been an update on both of these drugs at the ADA 85th Science Sessions conference.
